Search
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB11040ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals.
Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB11041ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals.
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB11042ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals.
Influenza B virus B/Massachusetts/2/2012 BX-51B antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB11046ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals.
Human papillomavirus type 33 L1 capsid protein antigen
go.drugbank.com/drugs/DB10311ApprovedInvestigationalIt is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 33. … The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Type 33 which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae
Human papillomavirus type 45 L1 capsid protein antigen
go.drugbank.com/drugs/DB10312ApprovedInvestigationalIt is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 45. … The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Type 45 which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae
Human papillomavirus type 58 L1 capsid protein antigen
go.drugbank.com/drugs/DB10314ApprovedInvestigationalIt is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 58. … The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Type 58 which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae
Formaldehyde
go.drugbank.com/drugs/DB03843ApprovedVet approvedFormaldehyde solution (formalin) is considered a hazardous compound, and its vapor toxic. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p717) … In solution, it has a wide range of uses: in the manufacture of resins and textiles, as a disinfectant, and as a laboratory fixative or preservative.
Inositol nicotinate
go.drugbank.com/drugs/DB08949ApprovedWithdrawnIt is associated with reduced flushing compared to other vasodilators by being broken down into the metabolites and inositol at a slower rate. … Nicotinic acid plays an essential role in many important metabolic processes and has been used as lipid-lowering agent.
Categories: Nicotinic Acid and DerivativesHuman papillomavirus type 31 L1 capsid protein antigen
go.drugbank.com/drugs/DB10310ApprovedInvestigationalIt is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 31. … The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Type 31 which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae